Description:This patent application embodies an intravenous formulation GMC1, GMC1 is a novel compound for the treatment of cancer and any other disease in which androgen, glucocorticoid and progesterone receptor function. The GMC1 molecule has shown excellent results in pre-clinical development which demonstrated the inhibition of tumor cell growth. Pre-clinical studies have also determined that GMC1 has a strong drug safety profile. The invention of a water-soluble and stable GMC1 formulation and a LC/MS/MS analytical method will enable further pre-clinical and clinical studies of GMC1. The unique mechanism of action of GMC1 has the potential to be a more potent and effective drug to treat metastatic prostate cancer.
Abstract:Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
Issue Date: 07/03/2018
Application Date: 03/28/2017
Post Date: 05/08/2018
UTEP Docket No: 2016-023
